These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30655860)

  • 1. Anti-neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP.
    He W; You Y; Du S; Lei T; Wang H; Li X; He X; Tong R; Wang Y
    Oncol Lett; 2019 Jan; 17(1):1008-1018. PubMed ID: 30655860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mangiferin induces apoptosis in human ovarian adenocarcinoma OVCAR3 cells via the regulation of Notch3.
    Zou B; Wang H; Liu Y; Qi P; Lei T; Sun M; Wang Y
    Oncol Rep; 2017 Sep; 38(3):1431-1441. PubMed ID: 28714011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells.
    Lu T; Sun L; Zhu X
    Biomed Pharmacother; 2018 Sep; 105():1269-1275. PubMed ID: 30021363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells.
    Wang X; Wu B; Zhong Z
    Oncol Lett; 2018 Jul; 16(1):585-593. PubMed ID: 29928445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mangiferin induces radiosensitization in glioblastoma cells by inhibiting nonhomologous end joining.
    Mu F; Liu T; Zheng H; Xie X; Lei T; He X; Du S; Tong R; Wang Y
    Oncol Rep; 2018 Dec; 40(6):3663-3673. PubMed ID: 30272350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
    Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
    Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H-Ferritin Affects Cisplatin-Induced Cytotoxicity in Ovarian Cancer Cells through the Modulation of ROS.
    Salatino A; Aversa I; Battaglia AM; Sacco A; Di Vito A; Santamaria G; Chirillo R; Veltri P; Tradigo G; Di Cello A; Venturella R; Biamonte F; Costanzo F
    Oxid Med Cell Longev; 2019; 2019():3461251. PubMed ID: 31781333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of YAP in lung cancer resistance to cisplatin.
    Song J; Xie LX; Zhang XY; Hu P; Long MF; Xiong F; Huang J; Ye XQ
    Oncol Lett; 2018 Sep; 16(3):3949-3954. PubMed ID: 30128013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
    Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
    Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms underlying mangiferin-induced apoptosis and cell cycle arrest in A549 human lung carcinoma cells.
    Shi W; Deng J; Tong R; Yang Y; He X; Lv J; Wang H; Deng S; Qi P; Zhang D; Wang Y
    Mol Med Rep; 2016 Apr; 13(4):3423-32. PubMed ID: 26935347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells.
    Xiao L; Shi XY; Zhang Y; Zhu Y; Zhu L; Tian W; Zhu BK; Wei ZL
    Onco Targets Ther; 2016; 9():1105-14. PubMed ID: 27073322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin.
    Sadhukhan P; Saha S; Dutta S; Sil PC
    Front Pharmacol; 2018; 9():638. PubMed ID: 29967581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.